��ժҪ��Ϣ

[an error occurred while processing this directive]

��Ƥ��Բ�ѧ��־ 2002, 28(2) 82-84 DOI: ISSN: 2096-5540 CN: 32-1880/R

��Ŀ¼ | ��Ŀ¼ | �� | �߼�� [��ӡ��ҳ] [�ر�]

��

	��չ��

	��Ϣ
	Supporting info
	PDFȫ��
	[HTMLȫ��]
	�ο��
	��뷴��
	�ѱ��Ƽ��
	��ҵ��
	��ù��
	��ñ��
	Email Alert
	��·��
	��Ϣ
	��Ĺؼ��
	��м��
	��س̶�ָ��
	��м��
	��
	��
	�ų��
	��
	��
	PubMed
	Article by
	Article by
	Article by

��м��س̶��ָ��о��״

�ų��, ��, ��

ɽ��ʡƤ��Բ��о��, ��250022

ժҪ��

��м��س̶�ָ��ַ��Ϊ��м��س̶��ָ��ٴ��ϵõ��˹㷺Ӧ�ú��Ͽɡ��м��س̶�ָ��ַ��ĸ��ȱ�ݡ��Լ��ʵ��о��һ��

�ؼ���� м�� س̶�ָ�� м��

Abstract:

Keywords:

�ո�� 2001-08-17 �޻�� ��淢��

DOI:

��Ŀ:

ͨѶ��:

��߼��:

�ο��ף�

[1] van de Kerkhof PC.The Psoriasis Area and Severity Index and ahemative approaches for the assessment of severity:persisting areas of confusion.Br J Dermatol,1997,137(4):661-662.
[2] Harari M,Shani J,Hristakieva E,et al.Clinical evaluation of a more rapid and sensitive Psoriasis Assessment Severity Score (PASS),and its comparison with the classic method of Psoriasis Area and Severity Index (PASI),before and after elimatotherapy at the Dead-Sea.Int J Dermatol,2000,39(12):913-918.
[3] Exam ML,Rapp SR,Feldman SR,et al.Measuring severity of psoriasis:methodological issues.J Dermatol Treat,1996,7:119-124.
[4] Marks R.Measurement of the response to treatment in psoriasis.J Dermatol Treat,1996,7 (Suppl 1):S7.
[5] Ramsay B,Lawrence CM.Measurement of involved surface area in patients with psoriasis.Br J Dermatol,1991,124(6):565-570.
[6] Faust HB,Gonin R,Chuang TY,et al.Reliabihty testing of the Dermatology index of disease severity (DIDS).An index for staging the severity of cutaneous inflammatory disease.Arch Dennatol,1997,133(11):1443-1448.
[7] Savolainen L,Kontinen J,Roning J,et al.Applieation of machine vision to assess involved surface in patients with psoriasis.Br J Dermatol,1997,137(3):395-400.
[8] Ashcroft DM,Wan Po AL,Williams HC,et al.Clinical measures of dis-ease severity and outcome in psoriasis:a critical appraisal of their quahty.Br J Dermatol,1999,141 (2):185-191.
[9] Snellman E,Maljanen T,Aromaa A,et al.Effect of hehotherapy on the cost of psoriasis.Br J Dermatol,1998,138(2):288-292.
[10] Feldman SR,Fleischer AB Jr,Reboussin DM,et al.The self-adminis-tered psoriasis area and severity index is valid and reliable.J Invest Dermatol,1996,106(1):183-186.
[11] Kirby B,Fortune DG,Bhushan M,et al.The Salford Psoriasis Index:an holistic measure of psoriasis severity.Br J Dermatol,2000,142 (4):728-732.
[12] Vardy DA,Guberman D,Lichtenstein DA,et al.Assessment of severity score in patients with psoriasis.Br J Dermatol,1993,129(3):349-350.
[13] Gonzalez S,Rajadhyaksha M,Anderson RR.Non-invasive (real-time)imaging of histologic margin of a proliferative skin lesion in vivo.J Invest Dermatol,1998,111(3):538-539.
[14] Ashcreft DM,Li Wan Po A,Williams HC,et al.Quality of life measures in psoriasis:a critical appraisal of their quality.J Clin Pharm Ther,1998,23(5):391-398.
[15] Mckenna KE,Stem RS.The outcomes movement and new measures of the severity of psoriasis.J Am Acad Dermatol,1996,34(3):534-538.
[16] Morgan M,McCreedy R,Simpson J,et al.Dermatology quality of life scales-a measure of the impact of skin diseases.Br J Dermatol,1997,136(2):202-206.
[17] Orem A,Deger O,Cimsit G,et al.Plasma polymorphonuclear leukocyte elastase levels and its relation to disease activity in psoriasis.Clin Claim Aeta,1997,264(1):49-56.
[18] De Pita O,Ruffelli M,Cadoni S,et al.Psoriasis:comparison of immuno-logical markers in patients with acute and remission phase.J Dermatol Sci,1996,13(2):118-24.